Key Highlights

  • Eli Lilly (NYSE:LLY) jumped 6.7 percent to USD 1,374.21 on October 29, 2026 after raising 2026 Revenue guidance to USD 91 billion to 92 billion, based on the closing data.
  • Third-quarter revenue was USD 24.4 billion against USD 22.6 billion expected, and adjusted Earnings were USD 7.48 per share against about USD 6.3, a large beat on both lines.
  • Adjusted earnings guidance was trimmed to USD 35 to 36 per share because of USD 4.57 per share of acquired Research and Development charges at Eli Lilly (NYSE:LLY).
  • The new obesity pill Foundayo reportedly fell short of expectations, a point that comes from published accounts and was not confirmed by company figures here.

A Large Beat and a Raised Outlook

Eli Lilly (NYSE:LLY) reported third-quarter results on October 29, 2026. Revenue of USD 24.4 billion beat the USD 22.6 billion consensus by about USD 1.8 billion, which is simple arithmetic on two published figures and a gap of roughly 8 percent. Adjusted earnings of USD 7.48 per share beat an estimate of about USD 6.3. Management raised 2026 revenue guidance to USD 91 billion to 92 billion. The shares closed up 6.7 percent at USD 1,374.21. Intraday gains of 4.4 percent to 6.7 percent appeared in different accounts depending on the timestamp, but the closing figure is 6.7 percent, and three published accounts confirm the results and the guidance. The company release remains the primary check on every figure, and the Earnings Per Share guidance was lowered in the same release.

Why Earnings Guidance Fell

The earnings outlook moved the other way. Adjusted earnings guidance was trimmed to USD 35 to 36 per share because acquired research and development charges of USD 4.57 per share are being counted. Such a charge appears when a drugmaker buys the rights to a drug in development, and it reduces adjusted profit in the period of purchase though it does not reduce revenue. The charge is a one-time cost of buying future products, so the trimmed guide does not mean the current Business is earning less. That explains how Eli Lilly (NYSE:LLY) could raise revenue guidance while trimming earnings guidance. Foundayo, the new obesity pill, reportedly fell short of expectations, and that claim comes from published accounts, so the size of the shortfall is not stated.

Risks and What to Watch

The first risk is expectations. A share price above USD 1,300 already assumes strong growth, and any slowdown in obesity drug Demand could weigh on it. The second risk is the new pill: if Foundayo sales stay below forecasts, revenue growth may rely on existing products at Eli Lilly (NYSE:LLY). A third is the market tone, since Nasdaq-100 futures were about 2.5 percent lower in premarket trading on October 30. Readers should check the company release for charge details and product sales. Watch the 9:30 a.m. ET open, analyst target changes and Novo Nordisk, which reports on Wednesday, November 4, 2026, as a read on the obesity drug market.

Where Things Stand

Eli Lilly (NYSE:LLY) jumped because revenue and adjusted earnings beat expectations by wide margins and 2026 revenue guidance was raised to USD 91 billion to 92 billion. The trimmed earnings guide reflects acquired research charges and not weaker sales. The evidence is strong, but the pill concern and a high share price keep the risks real, and Novo Nordisk's report on November 4 is a near catalyst.